Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
Abstract Background Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. We evaluated the safety and efficacy of buparlisib in patients with metas...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-11-01
|
Series: | Breast Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13058-020-01354-y |
id |
doaj-b135fa020eea478cb995d917e54e49ab |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ana C. Garrido-Castro Cristina Saura Romualdo Barroso-Sousa Hao Guo Eva Ciruelos Begoña Bermejo Joaquin Gavilá Violeta Serra Aleix Prat Laia Paré Pamela Céliz Patricia Villagrasa Yisheng Li Jennifer Savoie Zhan Xu Carlos L. Arteaga Ian E. Krop David B. Solit Gordon B. Mills Lewis C. Cantley Eric P. Winer Nancy U. Lin Jordi Rodon |
spellingShingle |
Ana C. Garrido-Castro Cristina Saura Romualdo Barroso-Sousa Hao Guo Eva Ciruelos Begoña Bermejo Joaquin Gavilá Violeta Serra Aleix Prat Laia Paré Pamela Céliz Patricia Villagrasa Yisheng Li Jennifer Savoie Zhan Xu Carlos L. Arteaga Ian E. Krop David B. Solit Gordon B. Mills Lewis C. Cantley Eric P. Winer Nancy U. Lin Jordi Rodon Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer Breast Cancer Research Buparlisib BKM120 Triple-negative breast cancer PI3K pathway Phase 1 |
author_facet |
Ana C. Garrido-Castro Cristina Saura Romualdo Barroso-Sousa Hao Guo Eva Ciruelos Begoña Bermejo Joaquin Gavilá Violeta Serra Aleix Prat Laia Paré Pamela Céliz Patricia Villagrasa Yisheng Li Jennifer Savoie Zhan Xu Carlos L. Arteaga Ian E. Krop David B. Solit Gordon B. Mills Lewis C. Cantley Eric P. Winer Nancy U. Lin Jordi Rodon |
author_sort |
Ana C. Garrido-Castro |
title |
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer |
title_short |
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer |
title_full |
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer |
title_fullStr |
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer |
title_full_unstemmed |
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer |
title_sort |
phase 2 study of buparlisib (bkm120), a pan-class i pi3k inhibitor, in patients with metastatic triple-negative breast cancer |
publisher |
BMC |
series |
Breast Cancer Research |
issn |
1465-542X |
publishDate |
2020-11-01 |
description |
Abstract Background Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. We evaluated the safety and efficacy of buparlisib in patients with metastatic triple-negative breast cancer. Methods This was a single-arm phase 2 study enrolling patients with triple-negative metastatic breast cancer. Patients were treated with buparlisib at a starting dose of 100 mg daily. The primary endpoint was clinical benefit, defined as confirmed complete response (CR), partial response (PR), or stable disease (SD) for ≥ 4 months, per RECIST 1.1. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and toxicity. A subset of patients underwent pre- and on-treatment tumor tissue biopsies for correlative studies. Results Fifty patients were enrolled. Median number of cycles was 2 (range 1–10). The clinical benefit rate was 12% (6 patients, all SD ≥ 4 months). Median PFS was 1.8 months (95% confidence interval [CI] 1.6–2.3). Median OS was 11.2 months (95% CI 6.2–25). The most frequent adverse events were fatigue (58% all grades, 8% grade 3), nausea (34% all grades, none grade 3), hyperglycemia (34% all grades, 4% grade 3), and anorexia (30% all grades, 2% grade 3). Eighteen percent of patients experienced depression (12% grade 1, 6% grade 2) and anxiety (10% grade 1, 8% grade 2). Alterations in PIK3CA/AKT1/PTEN were present in 6/27 patients with available targeted DNA sequencing (MSK-IMPACT), 3 of whom achieved SD as best overall response though none with clinical benefit ≥ 4 months. Of five patients with paired baseline and on-treatment biopsies, reverse phase protein arrays (RPPA) analysis demonstrated reduction of S6 phosphorylation in 2 of 3 patients who achieved SD, and in none of the patients with progressive disease. Conclusions Buparlisib was associated with prolonged SD in a very small subset of patients with triple-negative breast cancer; however, no confirmed objective responses were observed. Downmodulation of key nodes in the PI3K pathway was observed in patients who achieved SD. PI3K pathway inhibition alone may be insufficient as a therapeutic strategy for triple-negative breast cancer. Trial registration NCT01790932 . Registered on 13 February 2013; NCT01629615 . Registered on 27 June 2012. |
topic |
Buparlisib BKM120 Triple-negative breast cancer PI3K pathway Phase 1 |
url |
http://link.springer.com/article/10.1186/s13058-020-01354-y |
work_keys_str_mv |
AT anacgarridocastro phase2studyofbuparlisibbkm120apanclassipi3kinhibitorinpatientswithmetastatictriplenegativebreastcancer AT cristinasaura phase2studyofbuparlisibbkm120apanclassipi3kinhibitorinpatientswithmetastatictriplenegativebreastcancer AT romualdobarrososousa phase2studyofbuparlisibbkm120apanclassipi3kinhibitorinpatientswithmetastatictriplenegativebreastcancer AT haoguo phase2studyofbuparlisibbkm120apanclassipi3kinhibitorinpatientswithmetastatictriplenegativebreastcancer AT evaciruelos phase2studyofbuparlisibbkm120apanclassipi3kinhibitorinpatientswithmetastatictriplenegativebreastcancer AT begonabermejo phase2studyofbuparlisibbkm120apanclassipi3kinhibitorinpatientswithmetastatictriplenegativebreastcancer AT joaquingavila phase2studyofbuparlisibbkm120apanclassipi3kinhibitorinpatientswithmetastatictriplenegativebreastcancer AT violetaserra phase2studyofbuparlisibbkm120apanclassipi3kinhibitorinpatientswithmetastatictriplenegativebreastcancer AT aleixprat phase2studyofbuparlisibbkm120apanclassipi3kinhibitorinpatientswithmetastatictriplenegativebreastcancer AT laiapare phase2studyofbuparlisibbkm120apanclassipi3kinhibitorinpatientswithmetastatictriplenegativebreastcancer AT pamelaceliz phase2studyofbuparlisibbkm120apanclassipi3kinhibitorinpatientswithmetastatictriplenegativebreastcancer AT patriciavillagrasa phase2studyofbuparlisibbkm120apanclassipi3kinhibitorinpatientswithmetastatictriplenegativebreastcancer AT yishengli phase2studyofbuparlisibbkm120apanclassipi3kinhibitorinpatientswithmetastatictriplenegativebreastcancer AT jennifersavoie phase2studyofbuparlisibbkm120apanclassipi3kinhibitorinpatientswithmetastatictriplenegativebreastcancer AT zhanxu phase2studyofbuparlisibbkm120apanclassipi3kinhibitorinpatientswithmetastatictriplenegativebreastcancer AT carloslarteaga phase2studyofbuparlisibbkm120apanclassipi3kinhibitorinpatientswithmetastatictriplenegativebreastcancer AT ianekrop phase2studyofbuparlisibbkm120apanclassipi3kinhibitorinpatientswithmetastatictriplenegativebreastcancer AT davidbsolit phase2studyofbuparlisibbkm120apanclassipi3kinhibitorinpatientswithmetastatictriplenegativebreastcancer AT gordonbmills phase2studyofbuparlisibbkm120apanclassipi3kinhibitorinpatientswithmetastatictriplenegativebreastcancer AT lewisccantley phase2studyofbuparlisibbkm120apanclassipi3kinhibitorinpatientswithmetastatictriplenegativebreastcancer AT ericpwiner phase2studyofbuparlisibbkm120apanclassipi3kinhibitorinpatientswithmetastatictriplenegativebreastcancer AT nancyulin phase2studyofbuparlisibbkm120apanclassipi3kinhibitorinpatientswithmetastatictriplenegativebreastcancer AT jordirodon phase2studyofbuparlisibbkm120apanclassipi3kinhibitorinpatientswithmetastatictriplenegativebreastcancer |
_version_ |
1721554699207835648 |
spelling |
doaj-b135fa020eea478cb995d917e54e49ab2021-04-02T17:07:51ZengBMCBreast Cancer Research1465-542X2020-11-0122111310.1186/s13058-020-01354-yPhase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancerAna C. Garrido-Castro0Cristina Saura1Romualdo Barroso-Sousa2Hao Guo3Eva Ciruelos4Begoña Bermejo5Joaquin Gavilá6Violeta Serra7Aleix Prat8Laia Paré9Pamela Céliz10Patricia Villagrasa11Yisheng Li12Jennifer Savoie13Zhan Xu14Carlos L. Arteaga15Ian E. Krop16David B. Solit17Gordon B. Mills18Lewis C. Cantley19Eric P. Winer20Nancy U. Lin21Jordi Rodon22Department of Medical Oncology, Susan F. Smith Center for Women’s Cancers, Dana-Farber Cancer Institute, Harvard Medical SchoolDepartment of Medical Oncology, Vall d’Hebron University Hospital, Universitat Autònoma de BarcelonaDepartment of Medical Oncology, Susan F. Smith Center for Women’s Cancers, Dana-Farber Cancer Institute, Harvard Medical SchoolDivision of Biostatistics, Department of Data Sciences, Dana-Farber Cancer InstituteHospital 12 de OctubreClinic University Hospital, INCLIVA Biomedical Research Institute, CIBERONC-ISCIIIFundación Instituto Valenciano De OncologíaExperimental Therapeutics Group, Vall d’Hebron Institute of OncologyDepartment of Medical Oncology, Translational Genomics and Targeted Therapeutics in Solid Tumors, IDIBAPS, Hospital Clínic of BarcelonaSOLTI Breast Cancer Research GroupSOLTI Breast Cancer Research GroupSOLTI Breast Cancer Research GroupDepartment of Biostatistics, Division of Basic Sciences, The University of Texas MD Anderson Cancer CenterDepartment of Medical Oncology, Susan F. Smith Center for Women’s Cancers, Dana-Farber Cancer Institute, Harvard Medical SchoolSchool of Communication, Northern Arizona UniversityHarold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical CenterDepartment of Medical Oncology, Susan F. Smith Center for Women’s Cancers, Dana-Farber Cancer Institute, Harvard Medical SchoolKravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer CenterKnight Cancer Institute, Oregon Health & Science UniversitySandra and Edward Meyer Cancer Center, Weill Cornell Medical CollegeDepartment of Medical Oncology, Susan F. Smith Center for Women’s Cancers, Dana-Farber Cancer Institute, Harvard Medical SchoolDepartment of Medical Oncology, Susan F. Smith Center for Women’s Cancers, Dana-Farber Cancer Institute, Harvard Medical SchoolDepartment of Medical Oncology, Vall d’Hebron University Hospital, Universitat Autònoma de BarcelonaAbstract Background Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. We evaluated the safety and efficacy of buparlisib in patients with metastatic triple-negative breast cancer. Methods This was a single-arm phase 2 study enrolling patients with triple-negative metastatic breast cancer. Patients were treated with buparlisib at a starting dose of 100 mg daily. The primary endpoint was clinical benefit, defined as confirmed complete response (CR), partial response (PR), or stable disease (SD) for ≥ 4 months, per RECIST 1.1. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and toxicity. A subset of patients underwent pre- and on-treatment tumor tissue biopsies for correlative studies. Results Fifty patients were enrolled. Median number of cycles was 2 (range 1–10). The clinical benefit rate was 12% (6 patients, all SD ≥ 4 months). Median PFS was 1.8 months (95% confidence interval [CI] 1.6–2.3). Median OS was 11.2 months (95% CI 6.2–25). The most frequent adverse events were fatigue (58% all grades, 8% grade 3), nausea (34% all grades, none grade 3), hyperglycemia (34% all grades, 4% grade 3), and anorexia (30% all grades, 2% grade 3). Eighteen percent of patients experienced depression (12% grade 1, 6% grade 2) and anxiety (10% grade 1, 8% grade 2). Alterations in PIK3CA/AKT1/PTEN were present in 6/27 patients with available targeted DNA sequencing (MSK-IMPACT), 3 of whom achieved SD as best overall response though none with clinical benefit ≥ 4 months. Of five patients with paired baseline and on-treatment biopsies, reverse phase protein arrays (RPPA) analysis demonstrated reduction of S6 phosphorylation in 2 of 3 patients who achieved SD, and in none of the patients with progressive disease. Conclusions Buparlisib was associated with prolonged SD in a very small subset of patients with triple-negative breast cancer; however, no confirmed objective responses were observed. Downmodulation of key nodes in the PI3K pathway was observed in patients who achieved SD. PI3K pathway inhibition alone may be insufficient as a therapeutic strategy for triple-negative breast cancer. Trial registration NCT01790932 . Registered on 13 February 2013; NCT01629615 . Registered on 27 June 2012.http://link.springer.com/article/10.1186/s13058-020-01354-yBuparlisibBKM120Triple-negative breast cancerPI3K pathwayPhase 1 |